Abstract
Recent advances in our understanding of the mechanisms underlying immune responses have led to the development of new strategies designed to inhibit pathologic immune responses, such as autoimmunity, without severely compromising protective immune responses or causing serious toxic side effects. Many of these strategies are based on the two-signal model for T cell activation (1,2). The first signal occurs when the T cell receptor (TCR) recognizes an antigenic peptide displayed on the surface of an antigen-presenting cells (APC). The second signal is provided by other receptor-ligand pairs on T cells and APC. The presence or absence of this signal, also referred to as T cell costimulation, plays a critical role in determining whether antigen recognition through the TCR results in T cell activation or T cell unresponsiveness (1). Thus, the two-signal model implies that selective blockade of the second signal might render autoreactive T cells unresponsive in people with autoimmune diseases. As described below, this strategy has already been tested and has shown promise in animal models for autoimmunity, and it currently the subject of clinical investigation in humans.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. Marrack and J.W. Kappler, How the immune system recognizes the body, Sci. Am. 269, 80–89 (1993).
F.A. Harding, J.G. McArthur, J.A. Gross, D.H. Raulet, and J.P. Allison, CD28mediated signaling co-stimulates murine T cells and prevents induction of anergy in T cell clones, Nature 356, 607–610 (1992).
P. Tan, C. Anasetti, J.A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J.A. Ledbetter, and P.S. Linsley, Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1, J. Exp. Med. 177, 165–173 (1993).
M. F. Krummel and J.P. Allison, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J. Exp. Med. 182, 459–465 (1995).
P.J. Waterhouse, M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T. Mak, Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4, Science 270, 985–988 (1995).
J. A. Bluestone, New perspectives of CD28–B7-mediated T cell costimulation, Immunity 2, 555–559 (1995).
P.S. Linsley, W. Brady, M. Urnes, L. Gorsmaire, N.K. Damle, and J.A. Ledbetter, CTLA-4 is a second receptor for the B cell activation antigen B7, J Exp. Med. 174, 561–569 (1991).
P.S. Linsley, P.M. Wallace, J. Johnson, M.G. Gibson, J.L. Greene, J.A. Ledbetter, C. Singh, and M.A. Tepper, Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule, Science 257, 792–795 (1992).
D. R. Milich, P.S. Linsley, J.L. Hughes, and J.E. Jones, Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model, J. Immunol. 153, 429–435 (1994).
B.K. Finck, P.S. Linsley, and D. Wofsy, Treatment of murine lupus with CTLA4Ig, Science 265, 1225–1227 (1994).
D. I. Daikh, B.K.Finck, P.S. Linsley, D. Hollenbaugh, and D. Wofsy, Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways, J. Immunol. 159, 3104–3108 (1997).
F. H. Durie, T.M. Foy, S.R. Masters, J.D. Laman, and R.J. Noelle, The role of CD40 in the regulation of humoral and cell-mediated immunity, Immunol. Today 15, 406–411 (1994).
S.J. Klaus, I. Berberich, and E.A. Clark, CD40 and its ligand in the regulation of humoral immunity, Semin. Immunol. 6, 279–286 (1994).
C. Mohan, Y. Shi, J.D. Laman, and S.K. Datta, Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis, J. Immunol. 154, 1470–1480 (1995).
G.S. Early, W. Zhao, and C.M. Burns, Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice, J. Immunol. 157, 3159–3164 (1996).
N.D. Griggs, S.S. Agersborg, R.J. Noelle, J.A. Ledbetter, P.S. Linsley, and K.S.K. Tung, The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expression and pathogenic acquisition of self reactive T cells, J Exp. Med 183, 801–810 (1996).
J.R. Abrams, M.G. Lebwohl, C.A. Guzzo, B.V. Jegasothy, M.T. Goldfarb, B.S. Goffe, A. Menter, N.J. Lowe, G. Krueger, M.J. Brown, R.S. Weiner, M.J. Birkhofer, G.L. Warner, K.K. Berry, P.S. Linsley, J.G. Krueger, H.D. Ochs, S.L. Kelley, and S. Kang, CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris, J Clin. Invest. 103, 1243–1252 (1999).
J.C. Davis, M.C. Totoritis, T.A. Sklenar, and D. Wofsy, Results of a phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC131) in patients with systemic lupus erythematosus (SLE), Arthritis Rheum. 42, S281 (1999).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Daikh, D.I., Wofsy, D. (2001). Treatment of Autoimmunity by Inhibition of T Cell Costimulation. In: Gupta, S. (eds) Mechanisms of Lymphocyte Activation and Immune Regulation VIII. Advances in Experimental Medicine and Biology, vol 490. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1243-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1243-1_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5458-1
Online ISBN: 978-1-4615-1243-1
eBook Packages: Springer Book Archive